Relapse characteristics of patients with NLPHL treated in the HD16 and HD17 studies
| Study . | Gender . | Growth pattern at initial diagnosis . | NLPHL localization at initial diagnosis . | DS at iPET . | RT at first-line treatment . | Localization of relapse . | Second-line treatment . | Third-line treatment . |
|---|---|---|---|---|---|---|---|---|
| HD16 | Male | Typical | Supradiaphragmatic | 2 | No | IIS | RT alone | — |
| HD16 | Female | Typical | Supradiaphragmatic | 1 | No | IIS | Ibrutinib | Rituximab alone |
| HD16 | Female | Typical | Infradiaphragmatic | 3 | Yes | DiS | n/a | — |
| HD16 | Male | Variant | Supradiaphragmatic | 1 | No | IIS and DiS | HDCT + ASCT | — |
| HD16 | Male | Variant | Supradiaphragmatic | 4 | Yes | IIS and DiS | HDCT + ASCT | — |
| HD16 | Female | Variant | Infradiaphragmatic | 2 | No | IIS | RT alone | — |
| HD16 | Male | Variant | Infradiaphragmatic | 4 | Yes | DiS | R-BEACOPP | — |
| HD16 | Male | n/a | Supradiaphragmatic | 3 | Yes | DiS | Ibrutinib | HDCT + ASCT |
| HD16 | Male | n/a | Supradiaphragmatic | 4 | No∗ | IIS | HDCT + ASCT | — |
| HD17 | Male | n/a | Infradiaphragmatic | 4 | Yes | IIS | HDCT + ASCT | — |
| Study . | Gender . | Growth pattern at initial diagnosis . | NLPHL localization at initial diagnosis . | DS at iPET . | RT at first-line treatment . | Localization of relapse . | Second-line treatment . | Third-line treatment . |
|---|---|---|---|---|---|---|---|---|
| HD16 | Male | Typical | Supradiaphragmatic | 2 | No | IIS | RT alone | — |
| HD16 | Female | Typical | Supradiaphragmatic | 1 | No | IIS | Ibrutinib | Rituximab alone |
| HD16 | Female | Typical | Infradiaphragmatic | 3 | Yes | DiS | n/a | — |
| HD16 | Male | Variant | Supradiaphragmatic | 1 | No | IIS and DiS | HDCT + ASCT | — |
| HD16 | Male | Variant | Supradiaphragmatic | 4 | Yes | IIS and DiS | HDCT + ASCT | — |
| HD16 | Female | Variant | Infradiaphragmatic | 2 | No | IIS | RT alone | — |
| HD16 | Male | Variant | Infradiaphragmatic | 4 | Yes | DiS | R-BEACOPP | — |
| HD16 | Male | n/a | Supradiaphragmatic | 3 | Yes | DiS | Ibrutinib | HDCT + ASCT |
| HD16 | Male | n/a | Supradiaphragmatic | 4 | No∗ | IIS | HDCT + ASCT | — |
| HD17 | Male | n/a | Infradiaphragmatic | 4 | Yes | IIS | HDCT + ASCT | — |
IIS, initially involved site(s); DiS, distant site(s); HDCT, high-dose chemotherapy; n/a, not available; R-BEACOPP, rituximab, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone
This patient did not receive RT at the local investigator’s discretion despite a positive iPET result.